Titre : Galectine -3

Galectine -3 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Visual Acuity
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Galectine -3 : Questions médicales les plus fréquentes", "headline": "Galectine -3 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Galectine -3 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-17", "dateModified": "2025-02-11", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Galectine -3" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Galectines", "url": "https://questionsmedicales.fr/mesh/D037161", "about": { "@type": "MedicalCondition", "name": "Galectines", "code": { "@type": "MedicalCode", "code": "D037161", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.503.307" } } }, "about": { "@type": "MedicalCondition", "name": "Galectine -3", "alternateName": "Galectin 3", "code": { "@type": "MedicalCode", "code": "D037502", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Çiğdem Yücel", "url": "https://questionsmedicales.fr/author/%C3%87i%C4%9Fdem%20Y%C3%BCcel", "affiliation": { "@type": "Organization", "name": "Department of Biochemistry, University of Health Science, Ankara City Hospital, Ankara, Turkey." } }, { "@type": "Person", "name": "Aybeniz Civan Kahve", "url": "https://questionsmedicales.fr/author/Aybeniz%20Civan%20Kahve", "affiliation": { "@type": "Organization", "name": "Gazi University Faculty of Medicine, Department of Psychiatry, Ankara, Turkey." } }, { "@type": "Person", "name": "Işık Batuhan Çakmak", "url": "https://questionsmedicales.fr/author/I%C5%9F%C4%B1k%20Batuhan%20%C3%87akmak", "affiliation": { "@type": "Organization", "name": "Sungurlu State Hospital, Department of Psychiatry, Corum, Turkey." } }, { "@type": "Person", "name": "Erol Göka", "url": "https://questionsmedicales.fr/author/Erol%20G%C3%B6ka", "affiliation": { "@type": "Organization", "name": "University of Health Sciences, Ankara City Hospital, Department of Psychiatry, Ankara, Turkey." } }, { "@type": "Person", "name": "Massiullah Shafaq-Zadah", "url": "https://questionsmedicales.fr/author/Massiullah%20Shafaq-Zadah", "affiliation": { "@type": "Organization", "name": "Institut Curie, PSL Research University, U1143 INSERM, UMR3666 CNRS, Cellular and Chemical Biology Unit, 75248Paris Cedex 05, France." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Prediction of Visual Acuity in Patients With Microbial Keratitis.", "datePublished": "2022-10-17", "url": "https://questionsmedicales.fr/article/36256452", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/ICO.0000000000003129" } }, { "@type": "ScholarlyArticle", "name": "Average paraxial power of a lens and visual acuity.", "datePublished": "2023-05-02", "url": "https://questionsmedicales.fr/article/37130981", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-023-34010-4" } }, { "@type": "ScholarlyArticle", "name": "Impact of myopia control spectacle lenses with highly aspherical lenslets on peripheral visual acuity and central visual acuity with peripheral gaze.", "datePublished": "2023-03-14", "url": "https://questionsmedicales.fr/article/36916874", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/opo.13127" } }, { "@type": "ScholarlyArticle", "name": "Factors Affecting Visual Acuity and Central Visual Function in Glaucoma Patients With Myopia.", "datePublished": "2023-05-12", "url": "https://questionsmedicales.fr/article/37178947", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ajo.2023.05.012" } }, { "@type": "ScholarlyArticle", "name": "Measuring recognition visual acuity in young children - testability with the Waterloo Differential Acuity Test (WatDAT).", "datePublished": "2022-11-20", "url": "https://questionsmedicales.fr/article/36403264", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1080/08164622.2022.2141101" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Lectines", "item": "https://questionsmedicales.fr/mesh/D037102" }, { "@type": "ListItem", "position": 5, "name": "Galectines", "item": "https://questionsmedicales.fr/mesh/D037161" }, { "@type": "ListItem", "position": 6, "name": "Galectine -3", "item": "https://questionsmedicales.fr/mesh/D037502" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Galectine -3 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Galectine -3", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-06", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Galectine -3", "description": "Comment mesurer le taux de galectine-3 ?\nQuels tests sont utilisés pour le diagnostic ?\nLa galectine-3 est-elle un biomarqueur ?\nQuels médecins évaluent la galectine-3 ?\nPeut-on détecter la galectine-3 dans l'urine ?", "url": "https://questionsmedicales.fr/mesh/D037502?mesh_terms=Visual+Acuity&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Galectine -3", "description": "Quels symptômes sont liés à la galectine-3 ?\nLa galectine-3 cause-t-elle des douleurs ?\nY a-t-il des symptômes cardiaques associés ?\nLa galectine-3 est-elle liée à la fatigue ?\nQuels signes cliniques sont observés ?", "url": "https://questionsmedicales.fr/mesh/D037502?mesh_terms=Visual+Acuity&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Galectine -3", "description": "Comment prévenir l'augmentation de la galectine-3 ?\nL'exercice physique influence-t-il la galectine-3 ?\nY a-t-il des aliments à éviter ?\nLe stress affecte-t-il la galectine-3 ?\nDes suppléments peuvent-ils aider à la prévention ?", "url": "https://questionsmedicales.fr/mesh/D037502?mesh_terms=Visual+Acuity&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Galectine -3", "description": "Quels traitements ciblent la galectine-3 ?\nLa galectine-3 peut-elle être traitée par des médicaments ?\nY a-t-il des traitements naturels pour la galectine-3 ?\nLes traitements varient-ils selon la maladie ?\nLa thérapie génique peut-elle cibler la galectine-3 ?", "url": "https://questionsmedicales.fr/mesh/D037502?mesh_terms=Visual+Acuity&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Galectine -3", "description": "Quelles complications sont liées à la galectine-3 ?\nLa galectine-3 aggrave-t-elle les maladies ?\nY a-t-il des risques de cancer associés ?\nLa galectine-3 influence-t-elle la fibrose ?\nDes complications neurologiques sont-elles possibles ?", "url": "https://questionsmedicales.fr/mesh/D037502?mesh_terms=Visual+Acuity&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Galectine -3", "description": "Quels facteurs augmentent la galectine-3 ?\nLe tabagisme influence-t-il la galectine-3 ?\nL'âge est-il un facteur de risque ?\nLe stress chronique est-il un facteur de risque ?\nY a-t-il un lien avec les maladies auto-immunes ?", "url": "https://questionsmedicales.fr/mesh/D037502?mesh_terms=Visual+Acuity&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment mesurer le taux de galectine-3 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le taux de galectine-3 se mesure par un test sanguin spécifique." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour le diagnostic ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins et des examens d'imagerie peuvent être utilisés." } }, { "@type": "Question", "name": "La galectine-3 est-elle un biomarqueur ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle est considérée comme un biomarqueur pour certaines maladies." } }, { "@type": "Question", "name": "Quels médecins évaluent la galectine-3 ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les cardiologues et oncologues évaluent souvent la galectine-3." } }, { "@type": "Question", "name": "Peut-on détecter la galectine-3 dans l'urine ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "La galectine-3 est principalement mesurée dans le sang, pas dans l'urine." } }, { "@type": "Question", "name": "Quels symptômes sont liés à la galectine-3 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Elle est associée à des symptômes d'inflammation et de fibrose." } }, { "@type": "Question", "name": "La galectine-3 cause-t-elle des douleurs ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut contribuer à des douleurs liées à des maladies inflammatoires." } }, { "@type": "Question", "name": "Y a-t-il des symptômes cardiaques associés ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des symptômes comme l'essoufflement peuvent être présents." } }, { "@type": "Question", "name": "La galectine-3 est-elle liée à la fatigue ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut être associée à la fatigue dans des conditions inflammatoires." } }, { "@type": "Question", "name": "Quels signes cliniques sont observés ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme l'œdème et la dyspnée peuvent être observés." } }, { "@type": "Question", "name": "Comment prévenir l'augmentation de la galectine-3 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie sain, incluant une alimentation équilibrée, peut aider." } }, { "@type": "Question", "name": "L'exercice physique influence-t-il la galectine-3 ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exercice régulier peut réduire les niveaux de galectine-3." } }, { "@type": "Question", "name": "Y a-t-il des aliments à éviter ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Éviter les aliments transformés et riches en sucres peut être bénéfique." } }, { "@type": "Question", "name": "Le stress affecte-t-il la galectine-3 ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut augmenter les niveaux de galectine-3." } }, { "@type": "Question", "name": "Des suppléments peuvent-ils aider à la prévention ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Certains suppléments, comme les oméga-3, peuvent être bénéfiques." } }, { "@type": "Question", "name": "Quels traitements ciblent la galectine-3 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des inhibiteurs de galectine-3 sont en développement pour diverses maladies." } }, { "@type": "Question", "name": "La galectine-3 peut-elle être traitée par des médicaments ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains médicaments visent à réduire son activité dans le corps." } }, { "@type": "Question", "name": "Y a-t-il des traitements naturels pour la galectine-3 ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des approches diététiques et des suppléments peuvent aider à la réguler." } }, { "@type": "Question", "name": "Les traitements varient-ils selon la maladie ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements dépendent de la maladie associée à la galectine-3." } }, { "@type": "Question", "name": "La thérapie génique peut-elle cibler la galectine-3 ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Des recherches explorent la thérapie génique pour moduler son expression." } }, { "@type": "Question", "name": "Quelles complications sont liées à la galectine-3 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Elle est liée à des complications cardiovasculaires et pulmonaires." } }, { "@type": "Question", "name": "La galectine-3 aggrave-t-elle les maladies ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut aggraver des maladies comme l'insuffisance cardiaque." } }, { "@type": "Question", "name": "Y a-t-il des risques de cancer associés ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux élevés de galectine-3 sont associés à un risque accru de cancer." } }, { "@type": "Question", "name": "La galectine-3 influence-t-elle la fibrose ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle joue un rôle clé dans le développement de la fibrose tissulaire." } }, { "@type": "Question", "name": "Des complications neurologiques sont-elles possibles ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Des études suggèrent un lien entre galectine-3 et maladies neurodégénératives." } }, { "@type": "Question", "name": "Quels facteurs augmentent la galectine-3 ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "L'obésité, le diabète et l'inflammation chronique augmentent la galectine-3." } }, { "@type": "Question", "name": "Le tabagisme influence-t-il la galectine-3 ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme est un facteur de risque pour des niveaux élevés." } }, { "@type": "Question", "name": "L'âge est-il un facteur de risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les niveaux de galectine-3 augmentent souvent avec l'âge." } }, { "@type": "Question", "name": "Le stress chronique est-il un facteur de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut contribuer à des niveaux élevés de galectine-3." } }, { "@type": "Question", "name": "Y a-t-il un lien avec les maladies auto-immunes ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les maladies auto-immunes peuvent augmenter les niveaux de galectine-3." } } ] } ] }

Sources (10000 au total)

Prediction of Visual Acuity in Patients With Microbial Keratitis.

The purpose of this study was to predict visual acuity (VA) 90 days after presentation for patients with microbial keratitis (MK) from data at the initial clinical ophthalmic encounter.... Patients with MK were identified in the electronic health record between August 2012 and February 2021. Random forest (RF) models were used to predict 90-day VA < 20/40 [visual impairment (VI)]. Predi... One thousand seven hundred ninety-one patients were identified. The presenting logMAR VA was on average 0.86 (Snellen equivalent and standard deviation = 20/144 ± 12.6 lines) in the affected or worse ... RF modeling yielded good sensitivity and specificity to predict VI at 90 days which could guide clinicians about the risk of poor vision outcomes for patients with MK....

Impact of myopia control spectacle lenses with highly aspherical lenslets on peripheral visual acuity and central visual acuity with peripheral gaze.

Myopia control spectacle lenses with peripheral lenslets are gaining popularity because they are non-invasive and easy to manage, and ongoing clinical trials have shown promising results. This study a... High-contrast (100%) VA was measured at 300 cm and 10 lx. For each test, two lens designs were evaluated in counterbalanced order: a spectacle lens with highly aspherical lenslets (HALs) and a standar... Mean (SD) central VAs with peripheral gaze through the SVL and the HAL lens were 0.08 (0.13) and 0.17 (0.12) logMAR, respectively. The HAL lens reduced central VA with peripheral gaze by 0.10 (0.08) l... Under high-contrast and low-luminance conditions, the HAL lens reduced central VA with peripheral gaze by approximately one line compared with the SVL. The impact on central VA did not vary with gaze ...

Factors Affecting Visual Acuity and Central Visual Function in Glaucoma Patients With Myopia.

To investigate associated factors including structural parameters of myopia and vessel density (VD) using optical coherence tomography angiography (OCT-A) to visual acuity (VA) and central visual func... Retrospective cross-sectional study.... Sixty-five eyes of 60 glaucoma patients with myopia and without media opacity and retinal lesions were included. Both Swedish interactive thresholding algorithm (SITA) 24-2 and 10-2 visual field (VF) ... The worse mean deviation of SITA 24-2, thinner GCIPL thickness, and lower deep peripapillary VD were associated with the presence of central VF damage in glaucoma patients with myopia. Thinner GCIPL t... Decreased VA in glaucoma patients with myopia was associated with lower deep peripapillary VD and papillomacular bundle damage. Lower deep peripapillary VD was independently associated with decreased ...

Measuring recognition visual acuity in young children - testability with the Waterloo Differential Acuity Test (WatDAT).

Visual acuity measurement is important for the detection and monitoring of eye disorders. Developing accurate and sensitive visual acuity tests suitable for young children is therefore desirable.... Recognition or form visual acuity (VA), which is measured with matching in children aged 3 years and up, is more sensitive for detecting visual deficits compared to resolution VA. The Waterloo Differe... Fifty-one typically-developing children aged 12-36 months participated in the study. Data for Patti Pics (PP) and Face targets (FT) were collected for formats with 3, 4 and 5 distractors. The targets ... Of participants aged 18-36 months, 87% could perform the WatDAT PP targets with 3 distractors compared to 68% for the FT, while 48% could perform matching with PP. The testability for FT increased to ... WatDAT testability is higher than matching VA tests. This indicates that the newly developed WatDAT has potential for measuring recognition VA in children 18 months and older....

Agreement between a mobile applet-based visual acuity self-test program and the conventional method for distance and near visual acuity tests.

To investigate the agreement between a mobile applet-based visual acuity (VA) self-test program and the conventional VA tests.... This consecutive case series study included 121 children and adults (242 eyes). Patients were classified into three groups according to age (children, adolescents, and adults). They underwent uncorrec... Correlations among UDVA, DVA with ASC, UNVA, and NVA with ASC between the two methods were significant in all subjects (all p < 0.001). The intraclass correlation coefficient were 0.960, 0.845, 0.960,... There is good agreement between the mobile applet-based VA self-test program and the conventional VA tests. The VA self-test has good practical value especially in the current pandemic, allowing self-...

Evaluation of a visual acuity eHealth tool in patients with cataract.

To validate the Easee web-based tool for the assessment of visual acuity in patients who underwent cataract surgery.... University Eye Clinic Maastricht, Maastricht, the Netherlands.... Prospective method comparison study.... Subjects aged between 18 and 69 years who underwent cataract surgery on 1 or both eyes at the Maastricht University Medical Center+ were eligible to participate in this study. The uncorrected (UDVA) a... 46 subjects with 75 operated eyes were included in this study. The difference of the UDVA between the web-based tool and ETDRS or Snellen was -0.05 ± 0.10 logMAR ( P < .001 [0.15; -0.26]) and -0.04 ± ... The web-based tool was validated for the assessment of visual acuity in patients who underwent cataract surgery and showed clinically acceptable outcomes in up to 88% of patients. Most of the particip...

Early visual intervention, visual function analysis, and grating visual acuity outcomes in children with congenital Zika syndrome.

This study aimed to assess grating visual acuity and functional vision in children with congenital Zika syndrome.... Initial and final grating visual acuity was measured using Teller acuity cards. Cerebral vision impairment standardized tests were used to assess functional vision. Patients were referred to the early... In this study, 10 children were included with an age range of 1-37 months. Eight patients presented with macular atrophic scars. Neuroimaging revealed microcephaly and cerebral abnormalities in all pa... The grating visual acuity test revealed low vision in all children with congenital Zika syndrome. Functional vision evaluation revealed cerebral vision impairment characteristics in all patients, who ...